Close Menu

NEW YORK – Freenome announced today that it has closed a $160 million Series B financing round, which it will use to further develop its early cancer detection blood test.

The South San Francisco, California-based firm plans to perform a validation study and submit the first application of its platform, colorectal cancer screening, to the parallel review program of the US Food and Drug Administration and Centers for Medicare & Medicaid Services.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.